



# SECOND-QUARTER 2023 RESULTS

## TOTAL COMPANY

# \$10.0B 11.5%<sup>1</sup>

SALES  
WORLDWIDE

Organic\* sales growth for  
underlying base business\*\*

# \$1.08<sup>2</sup>

ADJUSTED DILUTED EPS

## CONTINUE TO FORECAST

# \$4.30 to \$4.50<sup>3</sup>

FULL-YEAR 2023 ADJUSTED DILUTED EPS

Reflects increased outlook for underlying base business  
offset by lower forecasted earnings contribution  
from COVID-19 testing-related sales

## BUSINESS HIGHLIGHTS

### BREAKING NEW GROUND IN LEADLESS PACEMAKERS

- ▶ FDA approval of AVEIR® DR Dual Chamber Leadless Pacemaker System, the world's first dual chamber leadless pacing system for people with abnormal or slow heart rhythms.
- ▶ Dual chamber, leadless synchronous or coordinated pacing is made possible with novel implant-to-implant (i2i™) communication technology.



### EXPANDING ACCESS TO LIFE-CHANGING TECHNOLOGIES

- ▶ In France, the FreeStyle Libre®\*\*\* 2 system is now the first and only continuous glucose monitoring (CGM) system to receive expanded national reimbursement to include all people with diabetes who use insulin.<sup>4</sup>
- ▶ In the U.S., the FreeStyle Libre® portfolio recently obtained significantly expanded coverage for Medicare beneficiaries.



## BUSINESS UNIT SALES



**\$4.3B**  
MEDICAL DEVICES



**\$2.3B**  
DIAGNOSTICS




**\$1.3B**  
ESTABLISHED  
PHARMACEUTICALS



**\$2.1B**  
NUTRITION

### INNOVATING TO TREAT ABNORMAL HEART RHYTHM

- ▶ FDA approval of TactiFlex® Ablation Catheter, Sensor Enabled™, the world's first ablation catheter with a unique flexible electrode tip and contact force sensing to treat patients with atrial fibrillation.
- ▶ When used with the EnSite™ X EP System, physicians have better visualization, allowing for more accuracy and precision with the TactiFlex Ablation Catheter.



\*Organic sales growth excludes the impact of foreign exchange, the impact of exiting the pediatric nutrition business in China, and the impact of the acquisition of Cardiovascular Systems, Inc. For full financial data and reconciliation of non-GAAP measures, please see our press release dated July 20, 2023, available at [www.abbottinvestor.com](http://www.abbottinvestor.com).

\*\*Excludes the impact of COVID-19 testing sales.

\*\*\*Find important safety information about the FreeStyle Libre portfolio: [www.freestylelibre.us/safety-information](http://www.freestylelibre.us/safety-information).

1. On a GAAP basis, second-quarter 2023 Abbott sales decreased 11.4%. 2. Second-quarter GAAP diluted EPS was \$0.78. 3. Abbott projects full-year 2023 diluted earnings per share from continuing operations under GAAP of \$3.02 to \$3.22. Abbott forecasts specified items for the full-year 2023 of \$1.28 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be \$4.30 to \$4.50 for the full-year 2023. 4. Reimbursement for people with Type 1, Type 2 MDI (more than 3 injections) and pump, Type 2 diabetes (ages 4 and above) on non-intensive insulin treatment (< 3 insulin injections per day) with insufficient glycemic control (HbA1c ≥ 8%).

#### FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.